Evidence map›Paper›PMID 40637969›Full record

ArticleDiscover oncology2025

Impact of Nintedanib on tumor angiogenesis and vascular normalization in a mouse model of colorectal cancer.

Naita M Wirsik, Jens M Seeger, Thomas Schmidt, Frank Hilberg, Hans F Fuchs, Christiane J Bruns, Oliver Coutelle, Hamid Kashkar, Lars M Schiffmann

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Naita M WirsikDepartment of General, Visceral, Thoracic and Transplant Surgery, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
Jens M SeegerInstitute for Molecular Immunology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
Thomas SchmidtDepartment of General, Visceral, Thoracic and Transplant Surgery, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
Frank HilbergBoehringer Ingelheim RCV, Doktor-Boehringer-Gasse 5-11, 1120, Vienna, Austria.
Hans F FuchsDepartment of General, Visceral, Thoracic and Transplant Surgery, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
Christiane J BrunsDepartment of General, Visceral, Thoracic and Transplant Surgery, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
Oliver CoutelleInstitute for Molecular Immunology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
Hamid KashkarInstitute for Molecular Immunology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
Lars M SchiffmannDepartment of General, Visceral, Thoracic and Transplant Surgery, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany. lars.schiffmann@uk-koeln.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFor many solid types of cancer including colorectal cancer treatment with the VEGF antibody bevacizumab as anti-angiogenic treatment has become standard of care. Nevertheless, long-term treatment with anti-angiogenic drugs in combination with other treatment modalities or alone can induce resistance through alternative pro-angiogenic pathways. In this study, we investigated the effects of nintedanib, an anti- VEGFR/PDGFR/FGFR kinase inhibitor, on tumor vasculature to determine the potential benefits of combined inhibition of multiple pro-angiogenic factors.

methodsIn a colorectal xenograft model, subcutaneous tumors were treated with Nintedanib. Tumor growth patterns were measured and tumors were analysed histologically regarding effects on tumor angiogenesis and parameters of vascular normalization.

resultsInhibition of VEGFR/PDGFR/FGFR by Nintedanib was able to reduce tumor growth by significantly inhibiting angiogenesis and inducing tumor cell death. The remaining vessels showed decreased vascular leakage and improved oxygen delivery, indicating a functionally and structurally improved vascular bed resulting from vascular normalization.

conclusionIn xenograft mouse model of colorectal cancer Nintedanib revealed anti-tumoral effects and induced vascular normalization. Our findings indicate that the treatment with Nintedanib could be able to improve intratumoral oxygen and thereby drug delivery to potentially enhance the efficacy of preexisting oncological therapies such as chemotherapy and radiation.

Identifiers

PMID40637969
PMCPMC12245745

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.